Prometheus Laboratories Inc., (Prometheus), a pharmaceutical and diagnostic company, has announced the commercial launch of three new cancer diagnostic products: ProOnc TumorSource, ProOnc Squamous and ProOnc Mesothelioma. Each of these tests is based on microRNA technology.
“Prometheus has a long and successful history of providing innovative diagnostics that complement targeted therapeutics to help physicians individualize patient care,” said Joseph M. Limber, president and chief executive officer of Prometheus. “Now we are proud to introduce the first three products from our cancer diagnostics portfolio with the launch of ProOncDx. We believe that these highly tissue-specific tests provide more objective and quantitative results than current methods, which, may lead to more personalized treatments for patients.”
ProOnc TumorSource identifies the tissue-of-origin of a metastatic tumor. The test identifies 25 different tumor types, including colon, liver, brain, breast, kidney, lung, ovary, pancreas, prostate and testis, and measures the expression level of 48 microRNA biomarkers. ProOnc TumorSource uses a proprietary classifier to assign a primary site to the cancer sample based on the microRNA expression in the tumor and may become a critical tool in the detection of cancer of unknown primary (CUP).
ProOnc Squamous classifies non-small cell lung carcinoma tumors into two histological groups: cancers of squamous histology and non-squamous cancers. The test measures the expression level of a squamous microRNA biomarker to differentiate patients that have squamous cell carcinoma of the lung from patients that have non-squamous non-small cell lung cancer.
ProOnc Mesothelioma is a cutting-edge molecular diagnostic test that uses microRNA to differentiate malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.
“MicroRNAs are small, non-coding sequences of RNA that are critically important in many biological and pathological processes,” said Harvey Pass, Professor of Cardiothoracic Surgery and Director of the Division of Thoracic Surgery and Thoracic Oncology at New York University Langone Medical Center and its NYU Cancer Institute. “The sensitivity and specificity of microRNA-based diagnostics should enable clinicians to differentiate particular cancer tissues with increased confidence, which may ultimately guide medical oncologists to deliver the safest and most efficacious therapy for their patients.”